<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://tickerreport.com/feed/</forum>
<forum_title>Ticker Report</forum_title>
<discussion_title>RBC Capital Markets Reaffirms Buy Rating for Vertex Pharmaceuticals Inc. (VRTX)</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.tickerreport.com/banking-finance/2084361/rbc-capital-markets-reaffirms-buy-rating-for-vertex-pharmaceuticals-inc-vrtx/</topic_url>
<topic_text>
Tweet 
RBC Capital Markets reissued their buy rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a report released on Tuesday morning. 
Shares of Vertex Pharmaceuticals ( NASDAQ:VRTX ) opened at 98.01 on Tuesday. The stock’s market capitalization is $24.28 billion. The firm’s 50-day moving average is $95.19 and its 200-day moving average is $88.19. Vertex Pharmaceuticals has a 1-year low of $75.90 and a 1-year high of $136.97. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.03. The company had revenue of $431.61 million for the quarter, compared to the consensus estimate of $428.08 million. The firm’s revenue was up 159.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.54) earnings per share. On average, analysts predict that Vertex Pharmaceuticals will post $1.04 earnings per share for the current fiscal year. 
A number of other analysts have also weighed in on VRTX. Robert W. Baird restated an outperform rating and issued a $128.00 target price (down from $144.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, May 1st. HC Wainwright restated a buy rating and issued a $155.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Piper Jaffray Cos. restated a buy rating on shares of Vertex Pharmaceuticals in a research note on Saturday, June 18th. Jefferies Group restated a buy rating and issued a $103.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, June 17th. Finally, Leerink Swann restated a buy rating on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Nine equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $120.43. 
In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,130 shares of the business’s stock in a transaction that occurred on Wednesday, June 29th. The stock was sold at an average price of $84.82, for a total value of $435,126.60. Following the sale, the director now owns 273,355 shares in the company, valued at approximately $23,185,971.10. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink . Also, Director Joshua S. Boger sold 6,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $99.63, for a total value of $687,447.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at approximately $27,370,851.75. The disclosure for this sale can be found here . 
Several hedge funds and institutional investors recently bought and sold shares of the company. Conning Inc. raised its position in Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock valued at $494,000 after buying an additional 20 shares during the period. Cleararc Capital Inc. raised its position in Vertex Pharmaceuticals by 0.6% in the first quarter. Cleararc Capital Inc. now owns 6,028 shares of the pharmaceutical company’s stock valued at $479,000 after buying an additional 33 shares during the period. Checchi Capital Advisers LLC raised its position in Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock valued at $152,000 after buying an additional 73 shares during the period. Greenwood Capital Associates LLC raised its position in Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock valued at $1,355,000 after buying an additional 80 shares during the period. Finally, Creative Planning raised its position in Vertex Pharmaceuticals by 2.0% in the second quarter. Creative Planning now owns 5,249 shares of the pharmaceutical company’s stock valued at $451,000 after buying an additional 102 shares during the period. 
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.   Vertex Pharmaceuticals Inc.   Vertex Pharmaceuticals Inc.  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.tickerreport.com/banking-finance/2084361/rbc-capital-markets-reaffirms-buy-rating-for-vertex-pharmaceuticals-inc-vrtx/</post_url>
<post_date>20160822</post_date>
<post_time>0748</post_time>
<username>Max Byerly</username>
<post>
Tweet 
RBC Capital Markets reissued their buy rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a report released on Tuesday morning. 
Shares of Vertex Pharmaceuticals ( NASDAQ:VRTX ) opened at 98.01 on Tuesday. The stock’s market capitalization is $24.28 billion. The firm’s 50-day moving average is $95.19 and its 200-day moving average is $88.19. Vertex Pharmaceuticals has a 1-year low of $75.90 and a 1-year high of $136.97. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.03. The company had revenue of $431.61 million for the quarter, compared to the consensus estimate of $428.08 million. The firm’s revenue was up 159.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.54) earnings per share. On average, analysts predict that Vertex Pharmaceuticals will post $1.04 earnings per share for the current fiscal year. 
A number of other analysts have also weighed in on VRTX. Robert W. Baird restated an outperform rating and issued a $128.00 target price (down from $144.00) on shares of Vertex Pharmaceuticals in a research note on Sunday, May 1st. HC Wainwright restated a buy rating and issued a $155.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Piper Jaffray Cos. restated a buy rating on shares of Vertex Pharmaceuticals in a research note on Saturday, June 18th. Jefferies Group restated a buy rating and issued a $103.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, June 17th. Finally, Leerink Swann restated a buy rating on shares of Vertex Pharmaceuticals in a research note on Thursday, April 28th. Nine equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $120.43. 
In other Vertex Pharmaceuticals news, Director Joshua S. Boger sold 5,130 shares of the business’s stock in a transaction that occurred on Wednesday, June 29th. The stock was sold at an average price of $84.82, for a total value of $435,126.60. Following the sale, the director now owns 273,355 shares in the company, valued at approximately $23,185,971.10. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this hyperlink . Also, Director Joshua S. Boger sold 6,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 17th. The shares were sold at an average price of $99.63, for a total value of $687,447.00. Following the completion of the sale, the director now owns 274,725 shares in the company, valued at approximately $27,370,851.75. The disclosure for this sale can be found here . 
Several hedge funds and institutional investors recently bought and sold shares of the company. Conning Inc. raised its position in Vertex Pharmaceuticals by 0.3% in the second quarter. Conning Inc. now owns 5,740 shares of the pharmaceutical company’s stock valued at $494,000 after buying an additional 20 shares during the period. Cleararc Capital Inc. raised its position in Vertex Pharmaceuticals by 0.6% in the first quarter. Cleararc Capital Inc. now owns 6,028 shares of the pharmaceutical company’s stock valued at $479,000 after buying an additional 33 shares during the period. Checchi Capital Advisers LLC raised its position in Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock valued at $152,000 after buying an additional 73 shares during the period. Greenwood Capital Associates LLC raised its position in Vertex Pharmaceuticals by 0.7% in the fourth quarter. Greenwood Capital Associates LLC now owns 10,768 shares of the pharmaceutical company’s stock valued at $1,355,000 after buying an additional 80 shares during the period. Finally, Creative Planning raised its position in Vertex Pharmaceuticals by 2.0% in the second quarter. Creative Planning now owns 5,249 shares of the pharmaceutical company’s stock valued at $451,000 after buying an additional 102 shares during the period. 
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.   Vertex Pharmaceuticals Inc.   Vertex Pharmaceuticals Inc.  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.tickerreport.com/logos/vertex-pharmaceuticals-logo.png</main_image>
</document>
